Day One

• An introduction to BIVDA, BIVDA working parties, and how BIVDA is supporting the delivery of the NHS 10-year plan and the Government’s Life Science Strategy
• The role diagnostics will play in delivering the NHS 3 shifts (Hospital to Community, Analogue to Digital, Treatment to Prevention)
• Creating a roadmap from innovation to adoption in the NHS

• Explore the latest biomarkers to advance clinical trial design, enrollment, and monitoring 
• Understand how to navigate biomarker development and CDx approval with confidence  
• Discover strategies for global trials and commercialisation under IVDR

• Understanding drivers and barriers for the adoption of biomarkers 
• Sharing J&Js approach to market shaping through agility and partnerships 
• Future perspectives on how to manage adoption in the evolving landscape and new CDx modalities, such as AI

• Explore the development and strategic rationale behind the TROP2 NMR computational biomarker
• Discuss how digital pathology and AI can solve large, looming questions in pathology
• Address the key barriers to computational pathology adoption, successful commercialisation and market enablement

A dedicated window for strategic 1:1 discussions and targeted networking, enabling attendees to strengthen key relationships and have purposeful conversations that drive meaningful outcomes in precision medicine.

• A decade of CDx development and commercialisation 
• How we address the needs of rapid and accessible testing globally
• A new era of rapid decentralised global NGS CDx solutions for pharma

• Defining ctDNA guided clinical trial designs and assay performance requirements for each
• Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
• Partnering on the development of a WGS MRD distributed kit

• Explore the evolving landscape of NGS-based liquid biopsy adoption and the remaining barriers to equitable access
• Discover how our decentralised approach and advanced analytics enable scalable, robust, and reproducible liquid biopsy testing, supported by real-world evidence from the deployment of MSK-ACCESS® powered with SOPHiA DDM™
• Gain insights into SOPHiA GENETICS’ unique hybrid CDx development and deployment model with diagnostic partners in key markets, streamlining regulatory pathways, accelerating execution, and enabling cost-efficiency at a global scale

• The lung cancer “liquid first” circulating tumour DNA pilot showed the feasibility of a national service: which is cost-effective and improves outcomes
• This led to a commissioned service in this setting and in breast cancer patients becoming resistant to treatment
• Future use cases include ctDNA as a marker of minimal residual disease to both escalate and de-escalate treatment following surgery or curative radiotherapy
• Barriers remain, including setting up “business as usual” services and educating the workforce in interpreting and using these new technologies

• A deep dive into epigenomic biomarkers within the precision oncology toolkit, and how methylation-based signatures reveal tumour biology beyond genomics
• An overview of emerging data demonstrating where epigenomic biomarkers deliver the greatest impact for patient stratification and trial enrichment
• A discussion of Guardant Health’s expanding global testing capabilities and their role in advancing epigenomics in clinical care

By Invitation Only